Hostname: page-component-84b7d79bbc-dwq4g Total loading time: 0 Render date: 2024-07-26T12:28:01.187Z Has data issue: false hasContentIssue false
  • English
  • Français

Socio-demographic, clinical and therapeutic features of patients treated for schizoaffective disorder using cannabis

Published online by Cambridge University Press:  19 July 2023

W. Bouali ,
W. Haouari ,
S. Brahim ,
N. Faouel  and
L. Zarrouk
W. Bouali*
Affiliation:
Psychiatrie, Faculty of Medicine of Monastir, Mahdia, Tunisia
W. Haouari
Affiliation:
Psychiatrie, Faculty of Medicine of Monastir, Mahdia, Tunisia
S. Brahim
Affiliation:
Psychiatrie, Faculty of Medicine of Monastir, Mahdia, Tunisia
N. Faouel
Affiliation:
Psychiatrie, Faculty of Medicine of Monastir, Mahdia, Tunisia
L. Zarrouk
Affiliation:
Psychiatrie, Faculty of Medicine of Monastir, Mahdia, Tunisia
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Psychotic disorders were formerly associated with cannabis use. It could accelerate the course of the illness and thus, constitutes a severity factor in terms of prognosis.

Objectives

To define the socio-demographic, clinical and therapeutic profiles of patients suffering from schizoaffective disorder (ASD) and who are consuming cannabis.

Methods

A retrospective study of 16 patients diagnosed with ASD, who were hospitalized at the psychiatric department of Tahar Sfar Mahdia’s hospital, and whose toxicology test results during the hospitalization came back positive for tetrahydrocannabinol.

Results

16 patients were gathered, all male, the average age was 26 years. The average age of first hospitalization was 25 years, 41.9% were unemployed. 76.3% of our sample were single. Three quarters of patients were hospitalized without consent. The average hospital stay was 30.33 days. Our patients had required during their stay an average dosage of antipsychotic, equivalent to chlorpromazine, of 752.42 +/- 342.79 mg. The average scores of psychometric scales were: BPRS = 55.72 +/- 14.11, SAPS = 41.5 +/- 14.80 and 42.11 +/- 18.88.

Conclusions

Currently, it is recognized that prolonged use of cannabis is an exogenous risk factor. The association between cannabis and schizoaffective disorder may amend the treatment modalities. It requires, thereby, an integrated and simultaneous treatment of schizophrenia and addictive behavior.

Disclosure of Interest

None Declared

Type
Abstract
Information
European Psychiatry , Volume 66 , Special Issue S1: Abstracts of the 31st European Congress of Psychiatry , March 2023 , pp. S679
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2023. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.